IL23A and cancer: On the other hand, evidences for the tumor suppressive function of the IL-23/Th17 axis have been described in B-acute lymphoblastic leukemia [19], myelodysplastic syndromes [50], hepatocellular carcinoma [51], in ovarian [52] and prostate [53] cancers.